Lilly to buy rights to Centrexion’s non-opoid pain asset CNTX-0290

This article was originally published here

CNTX-0290 is a small molecule somatostatin receptor type 4 (SSTR4) agonist, which is being evaluated for the treatment of chronic pain conditions in a phase 1 clinical trial.

The post Lilly to buy rights to Centrexion’s non-opoid pain asset CNTX-0290 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply